LANR
Lantern Reports Q3 2026 Results, Closes $4M Offering
Lantern Pharma achieved mixed operational results, with R&D costs decreasing by 36% while reporting a net loss. The company announced the engagement of the first clinical site for a TNBC trial and closed an approximately $4.0 million registered direct offering.